Harvesting Cells for Experimental Cancer Treatments

Korábbi kezelés

• Women of child-bearing potential who are pregnant because of the potentially dangerous effects of some of the procedures (e.g., tumor biopsy or surgery for tumor resection) on the fetus.
  • ELIGIBILITY CRITERIA FOR HEALTHY VOLUNTEERS:
• Is on steroid therapy or any other medication or has received vaccination that might interfere with cell preparation per Principal Investigator s (PI) discretion.
• Has received any type of organ transplant in the past 12 months.
• Has received a dura mater graft.

Más betegség

• Active systemic infections, coagulation disorders, or other major medical illnesses of the cardiovascular, respiratory, or immune system.
• Patients who cannot give proper informed consent to the experimental therapy due to an active psychiatric disorder or inability to understand the nature of the proposed therapy and attendant risk.
• Is at risk or has Creutzfeldt-Jakob Disease.
• Has ongoing illness that would cause harm to the volunteer during the apheresis procedure as determined by the PI.
• Has uncontrolled diabetes.
• Has a hematologic malignancy or any bleeding abnormalities.

Életkor

• Has had yellow jaundice, liver disease, or hepatitis since the age of 11.

Egyéb

• Has had babesiosis.
• Has undergone xenotransplantation at any time.
• If female, is pregnant or has given birth within the last six weeks.
• Has had an ear or body piercing or tattoos within the past 12 months.
• Has had a blood transfusion within the past 12 months.
• Has spent time outside the United States to a restricted country.
• Has participated in any high-risk activities.
• Whole blood donors who do not meet the DTM criteria for allogeneic whole blood donation.

• Patients must have a form of cancer currently being studied in the NCI-SB.
• Patient is able to understand and willing to sign a written informed consent document.
• Age greater than or equal to 18 years.
• Clinical performance status of ECOG 0 or 1.
• Serology
  • Seronegative for HIV antibody. (The experimental treatments being evaluated depend upon an intact immune system. Patients who are HIV seropositive can have decreased immune-competence and thus may be less responsive to the experimental treatment and more susceptible to its toxicities).
  • Seronegative for hepatitis B surface antigen and seronegative for hepatitis C antibody. If hepatitis C antibody test is positive, then the patient must be tested for the presence of antigen by RT-PCR and be HCV RNA negative.
• Lesions which will be harvested for the generation of TIL should be accessible via standard surgical or radiological techniques and be associated with acceptable morbidity.
• Age greater than or equal to 18 years.
• Non-reactive for HBsAg, anti-HBc, anti-HCV, anti-HIV-1/2, HBV/HCV/HIV-1 NAT, anti-HTLV-I/II, anti-T. cruzi, West Nile Virus NAT,syphilis, and babesia.
• PBMC donors must meet the strict behavioral and medical history requirements as per applicable NCI-SB Apheresis Donor SOP(s).
• Age greater than or equal to 18 years.
• Whole blood donors must meet the DTM inclusion criteria for allogeneic whole blood donation.

A regiszterben nem jelölt feltételek

• ELIGIBILITY CRITERIA FOR PATIENTS WITH A CURRENT DIAGNOSIS OF CANCER: